Medically reviewed on August 28, 2017.
Applies to the following strengths: 100 mg; 400 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Castleman's Disease
11 mg/kg intravenously over 1 hour every 3 weeks.
Duration of therapy: Until treatment failure.
-Siltuximab was not studied in patients with MCD who are HIV positive or HHV-8 positive because siltuximab did not bind to virally produced IL-6 in a nonclinical study.
Use: Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Renal Dose Adjustments
Mild to severe renal impairment (CrCl 15 mL/min to under 90 mL/min): No adjustment recommended.
End stage renal disease (CrCl less than 15 mL/min): Data not available
Liver Dose Adjustments
Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-If treatment criteria are not met a delay in treatment may be necessary; dose should not be reduced.
-Do not administer to patients with severe infections until the infection resolves.
-Perform hematology lab tests prior to each dose for the first 12 months and every 3 dosing cycles thereafter.
-Absolute Neutrophil Count should be 1.0 x 10(9)/L or higher before administration.
-Platelet count should be 75 × 10(9)/L or higher before first dose and 50 × 10(9)/L or higher before subsequent doses.
-Hemoglobin should be less than 17 g/dL before administration.
-Administer in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.
-Stop infusion if patient develops signs of anaphylaxis. Discontinue further therapy.
-Stop infusion if patient develops mild to moderate infusion reactions. If reaction resolves, infusion may be restarted at a lower infusion rate. Consider medication with antihistamines, acetaminophen, and corticosteroids. Discontinue if patient does not tolerate infusion following these interventions.
-Refrigerate; protect from light.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
-Do not infuse concomitantly in the same intravenous line with other agents.
-May lower resistance to infections. Contact your doctor immediately when symptoms suggesting infection appear in order to assure rapid evaluation and appropriate treatment.
-Discuss recommended vaccinations prior to treatment.
-Seek immediate medical attention for any symptoms of serious allergic reactions during the infusion. Signs include: difficulty breathing, chest tightness, wheezing, severe dizziness or light-headedness, swelling of the lips or skin rash.
-Patients of childbearing potential should avoid pregnancy which may include use of contraception during treatment and for 3 months after siltuximab therapy.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about siltuximab
- Siltuximab Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews
- Drug class: interleukin inhibitors
Other brands: Sylvant